NNC0471-0119 H insulin: pump pharmacology study
What this study tests
A completed Novo Nordisk phase 1 crossover study comparing investigational insulin NNC0471-0119 H against insulin aspart, each given as a pump bolus. Per the registry, it measures early glucose-lowering activity as the glucose infusion rate over the first hour after the bolus.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-09-10.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Per the registry, adults aged 18–64 with T1D for at least one year, pump use for at least 90 days and insulin requirements of 0.2–1.2 units/kg/day. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- The registry records 43 participants and completion in July 2025, but no results are posted. Completion does not establish that the insulin is faster, safer or available. The primary measure is glucose infusion needed during the first hour after a bolus.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: European Union. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- AUC(GIR,0-1h,basal-corrected): Area under the basal-corrected glucose infusion rate (GIR)-time curve from 0 to 1 hour — 0 to 1 hour after bolus infusion
The full picture
What the study asks
A completed Novo Nordisk phase 1 crossover study comparing investigational insulin NNC0471-0119 H against insulin aspart, each given as a pump bolus. Per the registry, it measures early glucose-lowering activity as the glucose infusion rate over the first hour after the bolus.
Who it involves
Adults aged 18–64 with T1D for at least one year, pump use for at least 90 days and insulin requirements of 0.2–1.2 units/kg/day. This is a summary; the full registry lists additional criteria.1
Design and timing
The registry lists 43 participants (actual enrollment). Primary completion: 2025-07-16 (actual). Study completion: 2025-07-28 (actual). Estimated dates can change and do not mean results are available.1
Evidence and limits
The registry records 43 participants and completion in July 2025, but no results are posted. Completion does not establish that the insulin is faster, safer or available. The primary measure is glucose infusion needed during the first hour after a bolus.
Sources
- [1]A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump (NCT06809621) · Trial registry — Protocol and current registry status checked 16 September 2026.
ClinicalTrials.gov. NCT06809621. Record checked 16 September 2026; last update posted 2026-09-10.